Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Takeda Pharmaceutical Co Ltd | 1,201 |
| 2 | Kissei Pharmaceutical Co Ltd | 168 |
| 3 | Pfizer Products Inc | 115 |
| 4 | Allergan Inc | 109 |
| 5 | Merck Patent GmbH | 59 |
| 6 | Gasherbrum Bio Inc | 58 |
| 7 | Pfizer Inc | 58 |
| 8 | Sumitomo Pharma Co Ltd | 58 |
| 9 | Wyeth LLC | 57 |
| 10 | Boehringer Ingelheim Pharma GmbH and Co KG | 53 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 3,903 |
| 2 | A61K | Medicinal preparations | 3,301 |
| 3 | C07D | Heterocyclic compounds | 2,219 |
| 4 | C07C | Acyclic and carbocyclic compounds | 484 |
| 5 | C07H | Sugars and derivatives | 382 |
| 6 | C07K | Peptides | 322 |
| 7 | C12N | Microorganisms, enzymes | 199 |
| 8 | C07F | Organometallic compounds | 171 |
| 9 | Y02A | Climate change adaptation | 167 |
| 10 | G01N | Investigating / analysing materials | 155 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Tolrestat or a salt thereof as an immuno-stimulating agent | 1988 | Wyeth LLC | 6 |
| Tolrestat for hearing impairment | 1988 | Wyeth LLC | 5 |
| Prodn. of methyl 5-bromo-6-methoxy-1-naphthoate - used as tolrestat intermediate, comprises reaction of methyl 6-methoxy-1-naphthoate with bromine in presence of oxidising agent | 1994 | Sanofi Aventis Deutschland GmbH | 2 |
| Tolrestat for wound healing | 1988 | Wyeth LLC | 1 |
| STABILIZED TOLRESTAT ROTATION ISOMER COMPOSITION | 1986 | Wyeth LLC | 1 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Aldose Reductase and Taurine | 5 |
| 2 | Drug-Induced Hepatotoxicity and Protection | 1 |
| 3 | Pain Mechanisms and Treatments | 1 |
| 4 | Quinazolinone synthesis and applications | 1 |
| 5 | Synthesis and Characterization of Heterocyclic Compounds | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Aruni Bhatnagar | University of Louisville | 23 |
| 2 | D. Dvornik | Princeton University | 12 |
| 3 | Akira Hara | Gifu Pharmaceutical University | 11 |
| 4 | Kota V. Ramana | The University of Texas Medical Branch at Galveston | 11 |
| 5 | Satish K. Srivastava | The University of Texas Medical Branch at Galveston | 11 |
| 6 | Peter F. Kador | National Eye Institute | 10 |
| 7 | Sanjay Srivastava | University of Louisville | 10 |
| 8 | David Hicks | Princeton University | 8 |
| 9 | Jane Millen | University of North Carolina at Chapel Hill | 8 |
| 10 | Janet Sredy | Women's Health Research Institute | 8 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options | 2005 | 525 | Heme Oxygenase-1 and Carbon Monoxide |
| Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy | 2009 | 347 | Pain Mechanisms and Treatments |
| PocketPicker: analysis of ligand binding-sites with shape descriptors | 2007 | 345 | Protein Structure and Dynamics |
| Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones | 2002 | 256 | Alcohol Consumption and Health Effects |
| Soft Docking and Multiple Receptor Conformations in Virtual Screening | 2004 | 236 | Computational Drug Discovery Methods |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Tolrestat?
Which pharmaceutical companies hold the most patents related to Tolrestat?
What are the main research topics associated with Tolrestat in the scientific literature?
What are the most commonly used CPC classifications for patents related to Tolrestat?
What therapeutic applications of Tolrestat are documented in the patent literature?